These valuable insights were obtained from a series of interviews conducted between 19th September and 8th October 2018 by the European Medical Journal with Prof Huub Schellekens, Dr Paul Cornes, and Prof Martin Dreyling. The topics discussed include the extent to which biosimilars can improve access to quality treatment in the context of high cost cancer therapies and the ways in which the potential economic advantages that biosimilars offer can be applied back to health systems.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles
5 Mins
29th
October
From Podium into Practice: Working Together to Revolutionise Cancer Care in the Real World
Cancer is on course to be the leading cause of death in the EU by 2035. Europe’s population is ageing rapidly, and obesity rates continue…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.
8 Mins
29th
October
Novel Approaches to Treat Glioblastoma Multiforme
Glioblastoma multiforme (GBM), central nervous system (CNS) WHO Grade 4 astrocytoma, is an almost uniformly lethal disease…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.
12 Mins
29th
October
Comparison of Breast Sensibility Following Breast Reconstruction with Two Different Techniques
Breast cancer is the most common cancer worldwide, accounting for 12.5% of all new cancer cases per year.1 According to the Spanish…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.